Is Zoetis (ZTS) overvalued or fairly valued?

MarketChacha shows Zoetis's valuation in context — a forward P/E of about 10.0, a price-to-book of about 9.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Zoetis (ZTS)?

Zoetis last traded at $74.21 (-1.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Zoetis

ZTS · NYSE · Healthcare · United States

$74.21-1.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:36 PM

Snapshot

TickerZTS

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees14,500

HeadquartersParsippany, United States

Market cap$31.1B

P/B9.5

Volume1.87M

Websitewww.zoetis.com

Filings tracked0

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions99.8%
Public & other0.0%

2,205 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.49%
Vanguard Capital Management LLC6.22%
Vanguard Portfolio Management LLC5.72%
State Street Corporation4.61%
State Farm Mutual Automobile Insurance Co3.79%
Morgan Stanley3.37%
Geode Capital Management, LLC2.71%
Wellington Management Group, LLP2.42%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $2.5B · EPS 1.85

Est. earnings growth +8.7%

Next fiscal year

Rev $10.1B · EPS 7.39

Est. earnings growth +7.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$71.4752-wk range$160.48

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about ZTS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.